Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Harpoon Therapeutics Inc. has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters are distributed among 3 distinct examiners and 2 distinct art units, so the portfolio spans more than one examination group while maintaining a separate examiner for each listed action.
DRISCOLL, MAUREEN VARINA is the busiest examiner, with 1 pending office action. The distribution supports tracking each matter independently and tailoring prosecution responses to the assigned examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DRISCOLL, MAUREEN VARINA | 1 | 66.0% | +40.7% |
| HADDAD, MAHER M | 1 | 50.6% | +53.8% |
| SKELDING, ZACHARY S | 1 | 59.8% | +41.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18635533 | CONDITIONAL ACTIVATION OF IMMUNOGLOBULIN MOLECULES | DRISCOLL, MAUREEN VARINA | — |
| 18457177 | COMBINATION THERAPY WITH IMMUNE CELL ENGAGING PROTEINS AND IMMUNOMODULATORS | HADDAD, MAHER M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18635533 | CONDITIONAL ACTIVATION OF IMMUNOGLOBULIN MOLECULES | DRISCOLL, MAUREEN VARINA | — |
| 18457177 | COMBINATION THERAPY WITH IMMUNE CELL ENGAGING PROTEINS AND IMMUNOMODULATORS | HADDAD, MAHER M | — |
| 18188037 | SINGLE CHAIN VARIABLE FRAGMENT CD3 BINDING PROTEINS | SKELDING, ZACHARY S | — |
| Art Unit | Apps |
|---|---|
| 1644 | 2 |
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18635533 | CONDITIONAL ACTIVATION OF IMMUNOGLOBULIN MOLECULES | DRISCOLL, MAUREEN VARINA | 1644 | §102§103§112Other | Non-Final OA | — | Pending | Apr 15, 2024 |
| 18457177 | COMBINATION THERAPY WITH IMMUNE CELL ENGAGING PROTEINS AND IMMUNOMODULATORS | HADDAD, MAHER M | 1641 | §102§103§112 | Non-Final OA | — | Pending | Aug 28, 2023 |
| 18188037 | SINGLE CHAIN VARIABLE FRAGMENT CD3 BINDING PROTEINS | SKELDING, ZACHARY S | 1644 | DP | Non-Final OA | — | Pending | Mar 22, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHarpoon Therapeutics Inc. has 3 pending office actions as of November 2026, spread across 2 art units and 3 examiners.
Maureen Varina Driscoll has the most, with 1 of Harpoon Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.